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Abstract
Wound healing is a fundamental process to re-establish 
tissue integrity. Microbial infections, however, may hinder 
this process and compromise our health. The increasing 
resistance of microorganisms colonizing infections to con-
ventional antibiotics has raised many concerns. Hence, new 
treatment options have been researched and new biomol-
ecules uncovered. As known, multicellular organisms are 
endowed with an arsenal of host-defense molecules, the 
Antimicrobial Peptides (AMPs) that fight microbial invaders 
and modulate the host’s immune response. In recent years, 
research has been focused on the development of such mol-
ecules with lower toxicity and improved activity compared 
to their endogenous counterparts for potential applications 
in wound healing. The present work offers a review over 
AMPs involved in wound healing and used against infected 
wounds, their potentialities and limitations, and highlights 
their mode of action. The challenges with the use of AMPs 
and the current strategies to prevent those challenges are 
also enumerated.
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Introduction
Skin is the largest organ in the human body. It works as a 
physical barrier, protecting our integrity from environmental 
threats. Inevitably wounds and traumas occur, compromising 
the skin defenses against pathogens and putting at risk our 
health [1]. In normal conditions, the skin heals by following a 
well-organized set of stages, hemostasis, inflammation, prolif-
eration and remodeling, in a process that may last few hours 
or days. However, under certain diminished health conditions, 
such as diabetes, infection, etc., the healing process may be de-
layed in a stage, usually at inflammation, and lead to the appear-
ance of chronic wounds. Chronic wounds are a result of gradual 
tissue degradation in which biochemical agents, like proteolytic 
enzymes, are involved becoming very difficult to treat. Chronic 
wounds are characterized by flawed tissue, debris impair heal-
ing, bacterial colonization (biofilms), prolonged inflammation, 
and moisture imbalance [2,3]. Hence, accelerate healing is vital 
to the human body as a mean to prevent wound chronicity and 
treat chronic wounds. 
In many chronic wound patients, the immune system is com-
promised. As such antimicrobial agents must be added to their 
treatment to fight infections. Traditional wound healing drugs 
include antiseptics, ointments, antibiotics, growth factors, cy-
tokines, plant derivates and even metal nanoparticles. Howev-
er, these have been proven difficult to translate into successful 
therapies for chronic wounds [4]. Considering the limitations of 
the previous strategies, such as high cost, low availability, re-
duced stability, specific and low antimicrobial activity, and re-
lease/delivery issues, Antimicrobial Peptides (AMPs) have been 
established as potential biomolecules for the healing of infected 
wounds [5,6].
AMPs are cationic, low molecular weight molecules and an 
integral part of the innate immune system, being present in 
many multicellular organisms, including insects, bacteria, ver-
tebrates, plants and humans. AMPs display a broad spectrum of 
antimicrobial activity, including microorganisms from resistant 
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strains, are bactericidal, their activity is not inhibited by biologi-
cal fluids, exudates or biofilms, and act quickly at multiple sites 
within microbial cells reducing chance of resistance. Since most 
microorganisms frequently found colonizing the wounded site 
are potentially pathogenic, infection control is critical [7-10].
The present work offers a review over the most common 
AMPs involved in wound healing and used against infected 
wounds, their potentialities and limitations. It also uncovers the 
most problematic aspects with skin infections and highlights 
the AMPs mode of action towards the pathogens colonizing the 
wounded site. Finally, a reflection over the recent advances in 
wound healing and the expectations for the future is provided.
Antimicrobial peptides in wound healing
At each stage of the healing process, the wounded site is in-
vaded by biomolecules responsible for inducing the consecutive 
phases. Between those, many antimicrobial agents that are part 
of our innate immune system, including AMPs, are attracted 
and activated to protect our system against foreign invaders. 
Upon tearing of the skin, proteases are activated and release 
Heparin Binding-Epidermal Growth Factors (HB-EGF) and am-
phiregulin that possess antimicrobial activity and are responsi-
ble for instigating the expression of epidermal AMPs later in the 
healing process [11]. During hemostasis, the complement and 
coagulation cascades are activated which results in the cleavage 
of many proteins like fibrinogen or thrombin. Fragments from 
those proteins give rise to many AMPs including the C3a, known 
for its antimicrobial activity [12]. 
In the inflammatory stage, the wounded site is invaded by 
neutrophils followed by monocytes and lymphocytes. Neu-
trophils are the most important “producers” of AMPs during 
inflammation; they contain α-defensins (human neutrophil 
peptides, HNPs) in azurophil granules, cathelicidins in specific 
granules (or large granules in rudiments), and calgranulins in 
the cytosol [2,13]. The defensins antibacterial and antiviral ac-
tivity is mainly exerted in the neutrophil phagolysosome, but 
they are also responsible for boosting bacterial phagocytosis by 
macrophages and possess chemotactic activity towards mono-
cytes, T cells and immature dendritic cells [14,15]. After release 
from the granules, cathelicidins are processed by the protei-
nase 3 into the antimicrobial peptide hCAP-18 or more com-
monly known the LL37, which is endowed with great antimicro-
bial activity [16]. Cathelicidins are also responsible for recruiting 
monocytes to the wounded site, for inducing the expression of 
the Vascular Endothelial Growth Factor (VEGF), and for causing 
the transactivation of the Epidermal Growth Factor (EGFR) and 
thus promoting keratinocytes migration [17-19]. The most com-
mon calgranulins found in the cytosol is the potent antifungal 
agent S100A8/S100A9 [20]. This AMP enhances phagocytosis 
and induces neutrophil chemotaxis and adhesion. It also me-
diates pro-inflammation by binding to the toll-like receptor 4 
(TLR-4) or the Receptor for Advanced Glycation End products 
(RAGE) and induces the expression of the cytokine interleukin 
10 (IL-10) [21-24]. 
During proliferation, most AMPs are obtained from the epi-
dermal keratinocytes, like hBD-2, hBD-3, RNase7 and psoriasin. 
At this stage the LL37 and S100A8/S100A9 together with the 
previous reach their peak of expression. As many defensins 
have the same ancestral gene, neutrophils (inflammation) and 
keratinocytes (proliferation) share many of the same AMPs and 
antimicrobial proteins. However, their expression is dependent 
on the healing phase [25,26]. For instance, the expression of 
hBD-3 is induced by the EGFR activation in epidermal keratino-
cytes upon injure, while the expression of S100A8/S100A9 can 
be both induced by the activation of growth factors during injury 
or by pro-inflammatory cytokines, thus linking growth and tissue 
regeneration with AMPs expression [26,27]. Epidermal AMPs 
involved in wound healing display a broad spectrum of antibac-
terial activity, with nBD-3 and RNase 7 being extremely effective 
against Staphylococcus aureus, psoriasin against Escherichia 
coli and calgranulins against Candida albicans [20,28,29]. Aside 
from protecting the wounded site from foreign invaders, the 
expression of these AMPs both during proliferation and inflam-
mation points to the manifestation of other non-antimicrobial 
functions conducted by these AMPs. It has been reported that 
hBD-2 activates dendritic cells through TLR-4, being a chemoat-
tractant towards immature dendritic cells and memory T cells, 
and has also been shown to stimulate proliferation, migration, 
and cytokine production of epidermal keratinocytes [30]. hBD-3 
and psoriasin have also shown chemoattractant properties, with 
the first also being associated with the activation of mast cells 
with increase of vascular permeability and the second expres-
sion of keratinocyte differentiation markers, promoting prolif-
eration of endothelial cells [25,31]. Tissue remodeling is the last 
stage of the healing process. Even though currently there are 
no evidences of AMPs being produced during this phase, the 
increase expression of the highly antimicrobial collagen type VI, 
characteristic of this phase, protects the connective tissue of 
the skin [32]. 
Wound infections: From single colonies to biofilms 
Skin infections are some of the most common bacterial in-
fections in humans. In hospitalized patients, bacterial skin in-
fections are the 28th most common diagnosis, with some of 
those infections already revealing resistance to antibiotics [33]. 
However, not all wounds containing bacteria are considered in-
fected; in fact, a wound that contains non-replicating bacteria is 
said to be contaminated, and those wounds containing replicat-
ing bacteria, but without causing cellular damage to the host, 
are said to be colonized. A wound is only considered infected 
when replicating bacteria invade the tissue and cause damage. 
Indeed, a major advance in the prevention and management 
of wound infection has been this understanding, that the mere 
presence of organisms in a wound is not an indication of infec-
tion and may not be more important than the level of bacterial 
growth. Bacterial infections can range from superficial, in which 
antibiotic administration may not be required, to complicated, 
in which biofilm formation is observed and systemic sepsis is a 
major problem with a lethal outcome [34,35]. In cases of skin 
rupture (most common in hospitalized patients recovering from 
surgery, burns or trauma), the chance of infection increases 
drastically. Wounds of surgical or traumatic origin, in which the 
host immune response is compromised, and the tissue is de-
vitalized (i.e ischemic, hypoxic or necrotic), bacteria coloniza-
tion is inevitable since these wounds offer optimal conditions 
for microbial growth. In these situations, infection has been 
defined as the product of entrance, growth, metabolic activity 
and resultant pathophysiologic effects of microorganisms in the 
wound bed. Since the human body is constantly surrounded by 
potentially pathogenic microorganisms, even in the absence 
of clinical infection, a delicate balance must exist between the 
host resistance and the actions of the bacteria to maintain our 
integrity. In fact, wound contaminants may originate from the 
environment, the surrounding skin (Staphylococcus epider-
midis, micrococci, skin diphtheroids, and propionibacteria are 
common in the normal skin microflora), and even from endog-
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enous sources involving mucous membranes [36-38]. In minor, 
healing wounds only a relatively small number of bacteria will 
take residence, while in devitalized tissues or chronic wounds 
colonization and establishment of a wide variety of endogenous 
microorganisms will occur, slowing the healing process. Bacte-
ria loads in excess of 105 microorganisms/g of tissue are con-
sidered to inhibit healing; this number depends, however, on 
the immune system of the host and the type of bacteria spe-
cies. The primary microorganisms causing delayed healing and 
infection in both acute and chronic wounds are Staphylococcus 
aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis 
and β-hemolytic Streptococcus bacteria [39]. Infected wounds 
may severely compromise the health of an individual. As such, 
efficient healing is essential in restoring the epidermal barrier 
natural characteristics and, with that, its bacterial resistance 
skills. 
Over the years, to aid with the healing process different 
biomolecules, drugs and ointments together with appropriate 
dressings have been proposed and researched. Silver, in ionic or 
nanocrystalline forms, has been used as an antimicrobial agent 
in the treatment of burns. Lately, the incorporation of silver in 
dressings has widen its use to other wound types that are either 
colonized or infected [40]. Povidone or cadexomer iodine, chlo-
rhexidine, polyhexamethyl biguanide and honey, all antiseptic 
agents, have also been used to impregnate dressings for acute 
and chronic wound care [41]. However, the rising of antibiotic-
resistant infection agents has increased the need for new al-
ternatives and more efficient therapies. Because of the AMPs 
ability to act at multiple sites within microbial cells in a very 
short time (smaller than the microorganism replicating cycle), 
bacteria are less likely to develop resistance; also AMPs display 
a broad spectrum, including resistant strains, are bactericidal 
and not just bacteriostatic, and their activity is not inhibited by 
body fluids, wound exudates or biofilms [2,7,10,42,43]. More 
importantly, AMPs are present in each phase of healing process 
contributing actively to the wound healing. Recently, studies 
have been conducted with the purpose of immobilizing AMPs 
onto the surface of wound dressings, to generate bioactive 
dressings, with promising results [10].
Antimicrobial peptides: Action mode against skin patho-
gens
Over 2500 AMPs with different origins and applications have 
been identified. Even though they present a broad antimicrobial 
action, AMPs can be classified by their primary target micro-
organisms: (i) Antibacterial, which target bacterial cell mem-
branes; (ii) Antiviral, which penetrate the viral envelope neutral-
izing their action; (iii) Antifungal, which act by targeting the cell 
wall or the intracellular organelles; and (iv) Antiparasitic, which 
kill by direct interaction with the cell wall. Most AMPs are small, 
cationic peptides composed of over 50% hydrophobic residues 
that enable them to fold into an amphiphilic conformation to 
better interact with the microorganisms’ cell membrane. AMPs 
mostly kill by disrupting the microorganism cell membrane in-
tegrity, which task can be accomplished in a matter of seconds 
after initial contact. For most cases the AMPs action starts with 
electrostatic attraction between the anionic cell wall of the mi-
croorganisms colonizing a wound and the cationic AMPs, which 
conformation then adapts to a cell membrane-water interface 
[2,44,45]. Once the interaction is established several models de-
scribing the AMPs transmembrane mechanisms of action against 
pathogens have been proposed. Table 1 and Figure 1 provide spe-
cific details describing the most common models used by AMPs.
Table 1: Description of AMPs transmembrane mechanisms of 
action against infectious pathogens [2,46].
Model Action Mode
Toroidal pore
Transmembrane pore model in which the pep-
tides insert perpendicularly in the lipid bilayer, 
inducing a local curvature. After binding to the 
phospholipid head groups, the AMPs align and 
insert into the membrane and cluster into un-
structured bundles that interact with water 
molecules generating channels within the mem-
brane. As the pores are transient upon disinte-
gration, some peptides may enter the cytoplasm 
and potentially target intracellular components.
Barrel stave
Transmembrane pore model in which the AMPs 
are initially oriented parallel to the membrane, 
forming staves, and eventually insert perpen-
dicularly to the plane of the lipid bilayer, form-
ing a barrel. This mechanism promotes lateral 
peptide-peptide interactions, with the hydro-
phobic regions interacting with the membrane 
lipids and the hydrophilic forming the lumen of 
the channels. The barrel-stave model is most 
common with AMPs with a minimum length of 
22 residues, if with an α-helical structure, or 8 
residues, if with a β-sheet structure.
Carpet-like
Transmembrane non-pore model in which the 
AMPs coat the microbial membrane up to satu-
ration, forming a "carpet", which leads to un-
favorable interactions and consequent loss of 
membrane integrity. As the membrane integrity 
is lost a detergent-like effect is accomplished in 
which the membrane gives rise to wormholes, 
causing the abrupt lysis of the microbial cell, and 
micelles are formed. The carpet model does not 
require specific peptide-peptide interactions 
nor the peptide to insert into the hydrophobic 
core to form transmembrane channels or spe-
cific peptide structures. 
Figure 1: Schematic representation of the most common AMPs 
transmembrane cell action models: Toroidal, barrel stave and car-
pet-like [47].
Aside from the models described above, in which AMPs kill 
bacteria via membrane permeabilization, there are others that 
act via non-membrane targets. Even though these are not as 
common some AMPs action mode consists in targeting the bac-
teria cell wall or intracellular organelles. In the first case, AMPs 
may inhibit the cell wall synthesis by interacting with specific 
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precursor molecules, for instance the lipid II. Here, the AMPs 
bind to the negatively charged pyrophosphate sugar moiety 
of lipid II leading to membrane disruption [48]. In the second 
case, AMPs interact with the cytoplasmic membrane first and 
then accumulate intracellularly, blocking critical cell processes, 
like protein/nucleic acid synthesis and disruption of enzymatic/
protein activity [49]. Additionally, AMPs may also recruit and 
activate immune cells that instigate microorganisms elimination 
and that intervene in the different healing phases [50]. As seen 
earlier, AMPs can induce a variety of immune responses during 
wound healing, including attraction, activation and differentia-
tion of white blood cells, stimulation of angiogenesis, reduction 
of pro-inflammatory cytokines expression, etc.
Challenges in wound healing: Antimicrobial peptides bio-
availability
In chronic wounds the excessive release of pro-inflammatory 
cytokines delays wound healing, retaining the process in the in-
flammatory phase. Hence, the AMPs action becomes most im-
portant, since their activity to neutralize bacteria is not direct 
but rather through the inhibition of pathogenicity factors or 
by controlling the host immune response. Even though AMPs 
can successfully retain their antimicrobial activity for millions of 
years and their immunomodulatory properties stay unaffected 
Table 2: Primary sequences and activities of selected natural- and synthetic-origin AMPs, most commonly employed in wound healing. 
AMPs Sequence Activity Ref.
LL37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES Promotes neovascularization, Migration and proliferation of epi-
thelial cells and is antimicrobial.
[54]
Pexiganan GIGKFLKKAKKFGKAFVKILKK Fights infection and stimulates migration of cells during tissue re-
modeling (already in phase III of clinical trials).
[55]
Tiger 17 WCKPKPKPRCH Promotes keratinocytes migration and proliferation, fibroblasts 
proliferation and re-epithelialization.
[56]
Esculentin-1-
a(1-21)NH2
GIFSKLAGKKIKNLLISGLKG
Promotes keratinocytes migration and skin re-epithelialization and 
is antimicrobial.
[57]
AH90 ATAWDFGPHGLLPIRPIRIRPLCG Stimulates the expression of transforming growth factors and an-
giogenesis and prevents excessive inflammation.
[58]
CW49 APFRMGICTTN Promotes macrophage recruitment during inflammation and up-
regulates pro-angiogenic proteins during tissue formation.
[59]
in contact with bacteria, they possess important limitations that 
hamper their clinical use, such as high production costs, poten-
tial toxicity and unknown pharmacokinetics. Indeed, one of the 
greatest challenges with the use of AMPs in wound healing is 
their availability in the market. So far very few AMPs have been 
thoroughly characterized and accepted in clinical trials, and 
from those even fewer have been approved by the US Food and 
Drug Administration (FDA). Most AMPs in clinical trials are ana-
logues of natural AMPs and the majority is limited to topical ap-
plications, due to systemic toxicity, susceptibility of the peptides 
to protease or enzymatic degradation and rapid kidney clear-
ance [45]. To circumvent these issues and improve the AMPs 
efficacy, different strategies have been proposed including the 
chemical modification of AMPs by including non-natural or D-
amino acids in their structure, shortening the peptides lengths, 
or induce amidation at the N-terminus to avoid peptide degra-
dation [51], the use of delivery vehicles, like liposome encap-
sulation [52], or the functionalization at the surface of wound 
dressings for a topical delivery [10]. Several AMPs have been 
synthesized and produced with promising topical effects, both 
in vitro and in vivo, on infected wounds [53]. Between the many 
that have been researched in skin infections, the ones listed in 
Table 2 have shown the most promising results, with some like 
pexiganan, already undergoing clinical trials. 
Antimicrobial efficacy of bioactive, fibrous dressings: In 
vitro evaluation 
Synthetic and natural-original polymers have been pro-
cessed in the form of fibrous mats or porous dressings and used 
as base substrates for the incorporation of bioactive molecules, 
like AMPs, for applications in skin regeneration and wound 
healing. In 2002, Kenawy et al. reported for the first time the 
incorporation of antibiotics within nanofiber meshes produced 
via electrospinning [60]. Metal oxide nanoparticles, like silver, 
zinc oxide and titanium dioxide have been widely researched 
for their antimicrobial potentialities and large surface area. 
AgNPs, for instance, have been loaded onto Polycaprolactone 
(PCL), Poly Vinyl Alcohol (PVA), chitosan or gelatin for topical 
and systemic administration with successful results against 
both Gram-positive and Gram-negative bacteria [61-63]. More 
recently, AMPs, which amino acids-based composition can be 
easily immobilized onto polymeric surfaces and structurally 
modified, have also been incorporate within polymeric matri-
ces for wound healing applications. For instance, the inverse-
Crabrolin AMP has been incorporated into PCL nanofibers with 
successful results against Escherichia coli and Bacillus subti-
lis [64]. The AMP motif Cys-KR12 originated from the human 
cathelicidin peptide LL37 has been immobilized onto electro-
spun silk fibroin nanofiber membranes, via click chemistry, and 
demonstrated great antimicrobial action against four pathogen-
ic bacterial strains (Staphylococcus aureus, Staphylococcus epi-
dermidis, Escherichia coli, and Pseudomonas aeruginosa), and 
to promote the keratinocytes and fibroblasts proliferation and 
differentiation [53]. Lysozyme and nisin AMPs were functional-
ized onto poly(acrylic acid) and PVA electrospun mats, reveal-
ing the capacity to completely eliminate Staphylococcus aureus 
bacteria colonies, and free the affected area within 14 days of 
incubation [65]. These are only some of the examples of the 
incorporation of AMPs into wound dressings and their potenti-
alities to fight microorganisms in infected wounds. Most of the 
previous studies implemented antimicrobial efficacy tests used 
in textile engineering, since most bioactive dressings are formed 
of nanofibrous, porous polymeric matrices, resembling fabrics. 
Generally, these antimicrobial tests are classified in qualitative, 
being the most common the agar diffusion method in which it 
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is also included the “halo” and “parallel streak” methods, and 
quantitative, in which both dynamic tests (“shake flask”) and in-
timate contact tests are included. Many bacterial strains may be 
employed; however, the Gram-positive bacteria Staphylococcus 
aureus and the Gram-negative bacteria Escherichia coli or Kleb-
siella pneumoniae are the standard. 
Agar Diffusion Method (“Halo” and “Parallel Streak”)
The agar diffusion method is a qualitative or semi-qualita-
tive test in which an antimicrobial agent in solution form or 
immobilized onto a fibrous surface diffuses into the surround-
ing agar forming a zone of bacterial inhibition. The standards 
AATCC 147-2004, JIS L 1902-2002 and ISO 20645:2004 are used 
to attain such results. In case of an antimicrobial solution, after 
spreading the bacteria along the agar plates, the solution can be 
poured onto punched-out wells of 6 mm diameter or injected 
into 6 mm diameter cellulose discs. In case of a fibrous dress-
ing, the “halo” method can be employed by mixing the bacteria 
with the agar, leaving it to solidify, and then pressing gently the 
mats’ against the agar. The “parallel streak” method requires for 
the formation of 3 to 5 lines above the agar using the bacteria 
inoculum and then covering partially the lines with the mats. 
Either way, the plates are then incubated at 37ºC for 18-24 h. 
The diffusion of the antimicrobial agent along the agar and 
the formation of a zone of inhibition are indicatives of the agent 
antimicrobial efficiency, while the size of the zone attests to its 
potency (Figure 2). However, it should be noticed that in many 
cases, when the antimicrobial agent is strongly attached to the 
dressing and there is no leaching a zone of inhibition does not 
appear. Instead, the samples should be removed, and the zone 
underneath analyzed. If a transparent, clear zone is observed, 
then the dressing is endowed with antimicrobial action by con-
tact.
Dynamic Method (“Shake Flask”)
The dynamic contact method, also known as “shake flask” 
method, follows the guidelines of the ASTM E2149-01, in which 
the efficacy of an immobilized antimicrobial agent will be evalu-
ated under dynamic environment. Briefly, the functionalized 
dressing is immersed in a bacteria suspension and submitted 
to regular shaking. After specific time periods aliquots of bacte-
ria suspension are collected and cultured to determine bacteria 
concentration. This method is both used to tests non-leaching 
and leaching antimicrobial agents due to its ease of process and 
simplicity of results treatment. It has been used for instance in 
Figure 2: Formation of zone of inhibition against S. aureus. 
(a) Chitosan (natural-origin polymer with antimicrobial properties) 
coated cotton gauze
(b) Bare cotton gauze. Data collected from the application of the 
standard ISO 20645: 2004 [66]. 
nanofibrous dressings loaded with tetracycline [67], amoxicillin 
[68], AgNPs [69] and even in chitosan polymeric blends [70], or 
to confirm the efficiency of antimicrobial nanofibrous filtration 
membranes of poly(vinyl alcohol) and poly(catechol) blends 
[63].
Intimate Contact Method 
This test is designed for antibacterial examination of textiles 
under intimate contact with bacteria suspensions. It follows the 
guidelines of the standards AATCC 100-2004 or the JIS L 1902-
2002 (quantitative option). Here, a small volume of bacteria in-
oculum is fully absorbed by a dressing sample and incubated 
in a humidified environment at 37ºC for 24 h. For hydrophobic 
surfaces intimate contact between bacteria and surface may be 
accomplished using a sterile glass slide of equal size as the sam-
ple gently pressed along the testing surface. After this period, 
a buffer is introduced, and the samples are submitted to strong 
shaking so the bacteria can be eluted and counted. This meth-
odology is best suited for non-leaching antimicrobial agents, 
since those leaching may quickly surround the cells and kill all 
bacteria in a very short period of incubation. For wound dress-
ings, the dynamic methods are the most appropriated since, 
when implanted, they are likely to be surrounded very quickly 
by biological fluids, wound exudates or blood, which will effec-
tively interact with the antimicrobial agent. 
Conclusions
The evolution of therapies for skin infections has been con-
stant. However, in the last decades, the advances have been 
more important, being now possible to fight infections while ac-
celerating healing using bioactive dressings loaded with AMPs, 
that still possess the abilities of traditional bandages (wound 
management and protection against repeated trauma). The in-
clusion of AMPs within wound dressings responds to an urgent 
need for more effective therapies to treat infected acute and 
chronic wounds, colonized by antibiotic resistant pathogens. 
This is still a fairly recent strategy and, as such, very little re-
searched. It is still necessary to understand the real impact of 
long-term therapies using functionalized AMPs in our innate im-
mune system, and the ability to control and manage the release 
of such antimicrobial agents upon contact with open wounds. 
The functionalized AMPs stability in physiological environment, 
their side effects, life-spam, and tunable performance, should 
be carefully investigated prior to entering the general market. 
In fact, despite the great efforts made by many researches, only 
a small number of AMPs are now available in the market or are 
in clinical trials. Nevertheless, it is expected that in few decades 
these limitations and concerns to be put to rest as new discov-
ers are being made every day on the structure, properties and 
benefits of AMPs for skin infections. 
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